DARZALEX FASPRO label expands across myeloma and AL amyloidosis
Updated prescribing information expands DARZALEX FASPRO use in multiple myeloma and AL amyloidosis while reinforcing safety, dosing, and monitoring.
This section contains the website’s posts.